Amicrobial pustulosis of the folds: long-term remission achieved with low dose dapsone and topical pimecrolimus
(Source: Dermatology Online Journal)
Source: Dermatology Online Journal - June 23, 2023 Category: Dermatology Authors: Brinia, Chrysa Source Type: research
Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study
Conclusions and RelevanceOur study found no evidence to support an association between TCI use and the risks of almost all cancers compared with TCS use in patients with AD, but physicians should be aware of potentially higher risks of leukemia with TCI use. This study represents the first population-based study focused on the cancer risk of TCI use among patients with AD in an Asian population. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 6, 2023 Category: Dermatology Source Type: research
Oleyl Alcohol May Be an Overlooked Allergen in Pimecrolimus Cream
Dermatitis. 2023 Jan 19. doi: 10.1089/derm.2022.0082. Online ahead of print.NO ABSTRACTPMID:36917544 | DOI:10.1089/derm.2022.0082 (Source: Dermatitis)
Source: Dermatitis - March 14, 2023 Category: Dermatology Source Type: research
Oleyl Alcohol May Be an Overlooked Allergen in Pimecrolimus Cream
Dermatitis. 2023 Jan 19. doi: 10.1089/derm.2022.0082. Online ahead of print.NO ABSTRACTPMID:36917544 | DOI:10.1089/derm.2022.0082 (Source: Dermatitis)
Source: Dermatitis - March 14, 2023 Category: Dermatology Source Type: research
Oleyl Alcohol May Be an Overlooked Allergen in Pimecrolimus Cream
Dermatitis. 2023 Jan 19. doi: 10.1089/derm.2022.0082. Online ahead of print.NO ABSTRACTPMID:36917544 | DOI:10.1089/derm.2022.0082 (Source: Dermatitis)
Source: Dermatitis - March 14, 2023 Category: Dermatology Source Type: research
Oleyl Alcohol May Be an Overlooked Allergen in Pimecrolimus Cream
Dermatitis. 2023 Jan 19. doi: 10.1089/derm.2022.0082. Online ahead of print.NO ABSTRACTPMID:36917544 | DOI:10.1089/derm.2022.0082 (Source: Dermatitis)
Source: Dermatitis - March 14, 2023 Category: Dermatology Source Type: research
Oleyl Alcohol May Be an Overlooked Allergen in Pimecrolimus Cream
Dermatitis. 2023 Jan 19. doi: 10.1089/derm.2022.0082. Online ahead of print.NO ABSTRACTPMID:36917544 | DOI:10.1089/derm.2022.0082 (Source: Dermatitis)
Source: Dermatitis - March 14, 2023 Category: Dermatology Source Type: research
Low-dose Pimecrolimus, an FDA-approved Calcineurin Inhibitor, Sensitizes Drug-resistant Cancer Cells < em > via < /em > Strong P-gp Inhibition
CONCLUSION: PIME, currently used in clinics, can be repositioned for treating patients with P-gp-over-expressing resistant cancer (stem) cells.PMID:36854528 | DOI:10.21873/anticanres.16255 (Source: Cell Research)
Source: Cell Research - February 28, 2023 Category: Cytology Authors: Jae Hyeon Park Ji Sun Lee Joo Kyung Shin Swati Sharma Hyung Sik Kim Sungpil Yoon Source Type: research
Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective
AbstractAtopic dermatitis (AD) is a common chronic, multisystem inflammatory skin disease in pediatric patients. There has been an increase in the incidence of AD in the pediatric population of the Asia –Pacific region. Studies have shown that genetic, epigenetic, environmental and cultural factors may lead to differences in the clinical manifestation and prevalence of AD between races. Early treatment of AD is necessary to prevent the atopic march leading to comorbidities such as asthma and alle rgic rhinitis. Topical corticosteroids (TCS) are used as first-line therapy for the treatment of AD, but their long-term usage...
Source: Dermatology and Therapy - February 3, 2023 Category: Dermatology Source Type: research
[TRANSLATED ARTICLE] Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36732114 | DOI:10.1016/j.farma.2022.12.016 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - February 2, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
[TRANSLATED ARTICLE] Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36732114 | DOI:10.1016/j.farma.2022.12.016 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - February 2, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
[TRANSLATED ARTICLE] Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36732114 | DOI:10.1016/j.farma.2022.12.016 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - February 2, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
Cancer Risk With Topical Pimecrolimus and Tacrolimus For Atopic Dermatitis: Systematic Review and Bayesian Meta-Analysis
Atopic dermatitis (AD) affects millions worldwide and is effectively managed by topical treatments, including the topical calcineurin inhibitors (TCIs), pimecrolimus and tacrolimus. In 2005 and 2011, the FDA released reviews associating TCIs with theoretical cancer risk, albeit uncertain. We systematically reviewed the cancer risk in patients with AD exposed to TCIs. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Alexandro Chu, Niveditha Devasenapathy, Melanie Wong, Archita Srivastava, Clement Lin, Renata Ceccacci, Margaret MacDonald, Derek Chu, for the AAAAI/ACAAI Joint Task Force on Practice Parameters Source Type: research
Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36710223 | DOI:10.1016/j.farma.2022.12.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - January 29, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
